Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Obamacare Repeal May Be Delaying User Fee Bill, Rep. DeGette Says

Executive Summary

House Energy and Commerce Committee Democrat says few in-depth member talks about the user fee bill have taken place because of focus on ACA repeal and replacement.

You may also be interested in...



User Fee Bill Could Become Ensnared In US Abortion Politics

Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.

Cosmetics Stakeholders Race To Hitch Reform Provisions To FDA User-Fee Bills

The Personal Care Products Council says consensus has nearly been reached between industry and consumer advocates on cosmetics reform provisions they hope to attach to FDA user-fee legislation. The groups must produce broadly supported, noncontroversial language by mid-March in order to have a shot at inclusion in the critical reauthorization bills, which typically pass well in advance of October deadlines.

Bill To Speed ANDA Approvals Gets Cool Reception From Industry, US FDA

At House hearing, FDA and AAM highlight logistical challenges of legislation's six-month ANDA review goal and potential to put GDUFA II agreement at risk.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS120003

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel